Immune checkpoint inhibitors and targeted therapies for metastatic melanoma: A network meta-analysis

Cancer Treatment Reviews

Volumn 54, Issue , 2017, Pages 34-42

  Pasquali, Sandro ^a   Chiarion Sileni, Vanna ^b   Rossi, Carlo Riccardo ^a,b   Mocellin, Simone ^a,b  

^a UNIVERSITY OF PADOVA   (Italy)

^b VENETO INSTITUTE OF ONCOLOGY IOV IRCCS   (Italy)

Author keywords

Immune checkpoint inhibitor; Melanoma; Metastatic; Network meta analysis; Targeted therapy

Indexed keywords

ANTINEOPLASTIC AGENT; B RAF KINASE INHIBITOR; COBIMETINIB; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4 ANTIBODY; DABRAFENIB; DACARBAZINE; IPILIMUMAB; MITOGEN ACTIVATED PROTEIN KINASE KINASE INHIBITOR; MONOCLONAL ANTIBODY; NIVOLUMAB; PEMBROLIZUMAB; TEMOZOLOMIDE; TICILIMUMAB; TRAMETINIB; VEMURAFENIB; B RAF KINASE; BRAF PROTEIN, HUMAN; CTLA4 PROTEIN, HUMAN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; MITOGEN ACTIVATED PROTEIN KINASE KINASE KINASE; PDCD1 PROTEIN, HUMAN; PROGRAMMED DEATH 1 RECEPTOR;

CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; DRUG EFFICACY; DRUG POTENTIATION; EVIDENCE BASED PRACTICE; HUMAN; META ANALYSIS (TOPIC); METASTATIC MELANOMA; MOLECULARLY TARGETED THERAPY; NETWORK META-ANALYSIS; PHASE 2 CLINICAL TRIAL (TOPIC); PROGRESSION FREE SURVIVAL; QUALITY CONTROL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SYSTEMATIC ERROR; SYSTEMATIC REVIEW; UNSPECIFIED SIDE EFFECT; ANTAGONISTS AND INHIBITORS; DISEASE FREE SURVIVAL; GENETICS; IMMUNOLOGY; MELANOMA; META ANALYSIS; MORTALITY; PATHOLOGY; PROCEDURES; TREATMENT OUTCOME;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CTLA-4 ANTIGEN; DISEASE-FREE SURVIVAL; HUMANS; MAP KINASE KINASE KINASES; MELANOMA; MOLECULAR TARGETED THERAPY; PROGRAMMED CELL DEATH 1 RECEPTOR; PROTO-ONCOGENE PROTEINS B-RAF; TREATMENT OUTCOME;

EID: 85012115778     PISSN: 03057372     EISSN: 15321967     Source Type: Journal    
DOI: 10.1016/j.ctrv.2017.01.006     Document Type: Review

References (74)

1. [1] Eggermont, A.M., Spatz, A., Robert, C., Cutaneous melanoma. Lancet 383 (2014), 816–827.
2. [2] Thompson, J.F., Scolyer, R.A., Kefford, R.F., Cutaneous melanoma. Lancet 365 (2005), 687–701.
3. [3] Crosby, T., Fish, R., Coles, B., Mason, M.D., Systemic treatments for metastatic cutaneous melanoma. Cochrane Database Syst Rev, 2000, CD001215.
4. [4] Garbe, C., Eigentler, T.K., Keilholz, U., Hauschild, A., Kirkwood, J.M., Systematic review of medical treatment in melanoma: current status and future prospects. Oncologist 16 (2011), 5–24.
5. [5] Ives, N.J., Stowe, R.L., Lorigan, P., Wheatley, K., Chemotherapy compared with biochemotherapy for the treatment of metastatic melanoma: a meta-analysis of 18 trials involving 2621 patients. J Clin Oncol 25 (2007), 5426–5434.
6. [6] Sasse, A.D., Sasse, E.C., Clark, L.G., Ulloa, L., Clark, O.A., Chemoimmunotherapy versus chemotherapy for metastatic malignant melanoma. Cochrane Database Syst Rev, 2007, CD005413.
7. [7] Chapman, P.B., Hauschild, A., Robert, C., Haanen, J.B., Ascierto, P., Larkin, J., et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 364 (2011), 2507–2516.
8. [8] Eggermont, A.M., Robert, C., New drugs in melanoma: it's a whole new world. Eur J Cancer 47 (2011), 2150–2157.
9. [9] Hodi, F.S., O'Day, S.J., McDermott, D.F., Weber, R.W., Sosman, J.A., Haanen, J.B., et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363 (2010), 711–723.
10. [10] Bronte, V., Mocellin, S., Suppressive influences in the immune response to cancer. J Immunother 32 (2009), 1–11.
11. [11] Mellman, I., Coukos, G., Dranoff, G., Cancer immunotherapy comes of age. Nature 480 (2011), 480–489.
12. [12] Pardoll, D.M., The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 12 (2012), 252–264.
13. [13] O'Day, S.J., Hamid, O., Urba, W.J., Targeting cytotoxic T-lymphocyte antigen-4 (CTLA-4): a novel strategy for the treatment of melanoma and other malignancies. Cancer 110 (2007), 2614–2627.
14. [14] Wolchok, J.D., Neyns, B., Linette, G., Negrier, S., Lutzky, J., Thomas, L., et al. Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study. Lancet Oncol 11 (2010), 155–164.
15. [15] Chiarion-Sileni, V., Pigozzo, J., Ascierto, P.A., Simeone, E., Maio, M., Calabro, L., et al. Ipilimumab retreatment in patients with pretreated advanced melanoma: the expanded access programme in Italy. Br J Cancer 110 (2014), 1721–1726.
16. [16] Delyon, J., Maio, M., Lebbe, C., The ipilimumab lesson in melanoma: achieving long-term survival. Semin Oncol 42 (2015), 387–401.
17. [17] Maio, M., Grob, J.J., Aamdal, S., Bondarenko, I., Robert, C., Thomas, L., et al. Five-year survival rates for treatment-naive patients with advanced melanoma who received ipilimumab plus dacarbazine in a phase III trial. J Clin Oncol 33 (2015), 1191–1196.
18. [18] Schadendorf, D., Hodi, F.S., Robert, C., Weber, J.S., Margolin, K., Hamid, O., et al. Pooled analysis of long-term survival data from phase II and phase III trials of ipilimumab in unresectable or metastatic melanoma. J Clin Oncol 33 (2015), 1889–1894.
19. [19] Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J.J., Cowey, C.L., Lao, C.D., et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med 373 (2015), 23–34.
20. [20] Postow, M.A., Chesney, J., Pavlick, A.C., Robert, C., Grossmann, K., McDermott, D., et al. Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N Engl J Med 372 (2015), 2006–2017.
21. [21] Robert, C., Long, G.V., Brady, B., Dutriaux, C., Maio, M., Mortier, L., et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med 372 (2015), 320–330.
22. [22] Robert, C., Schachter, J., Long, G.V., Arance, A., Grob, J.J., Mortier, L., et al. Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med 372 (2015), 2521–2532.
23. [23] Gray-Schopfer, V., Wellbrock, C., Marais, R., Melanoma biology and new targeted therapy. Nature 445 (2007), 851–857.
24. [24] Nikolaou, V.A., Stratigos, A.J., Flaherty, K.T., Tsao, H., Melanoma: new insights and new therapies. J Invest Dermatol 132 (2012), 854–863.
25. [25] Flaherty, K.T., Hodi, F.S., Fisher, D.E., From genes to drugs: targeted strategies for melanoma. Nat Rev Cancer 12 (2012), 349–361.
26. [26] Queirolo, P., Picasso, V., Spagnolo, F., Combined BRAF and MEK inhibition for the treatment of BRAF-mutated metastatic melanoma. Cancer Treat Rev 41 (2015), 519–526.
27. [27] Hauschild, A., Grob, J.J., Demidov, L.V., Jouary, T., Gutzmer, R., Millward, M., et al. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet 380 (2012), 358–365.
28. [28] McArthur, G.A., Chapman, P.B., Robert, C., Larkin, J., Haanen, J.B., Dummer, R., et al. Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study. Lancet Oncol 15 (2014), 323–332.
29. [29] Flaherty, K.T., Infante, J.R., Daud, A., Gonzalez, R., Kefford, R.F., Sosman, J., et al. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med 367 (2012), 1694–1703.
30. [30] Larkin, J., Ascierto, P.A., Dreno, B., Atkinson, V., Liszkay, G., Maio, M., et al. Combined vemurafenib and cobimetinib in BRAF-mutated melanoma. N Engl J Med 371 (2014), 1867–1876.
31. [31] Long, G.V., Stroyakovskiy, D., Gogas, H., Levchenko, E., de Braud, F., Larkin, J., et al. Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma. N Engl J Med 371 (2014), 1877–1888.
32. [32] Robert, C., Karaszewska, B., Schachter, J., Rutkowski, P., Mackiewicz, A., Stroiakovski, D., et al. Improved overall survival in melanoma with combined dabrafenib and trametinib. N Engl J Med 372 (2015), 30–39.
33. [33] Flaherty, K.T., Sosman, J.A., Atkins, M.B., New options and new questions: how to select and sequence therapies for patients with metastatic melanoma. Am Soc Clin Oncol Educ Book, 2012, 524–530.
34. [34] Jang, S., Atkins, M.B., Which drug, and when, for patients with BRAF-mutant melanoma?. Lancet Oncol 14 (2013), e60–e69.
35. [35] Menzies, A.M., Long, G.V., Systemic treatment for BRAF-mutant melanoma: where do we go next?. Lancet Oncol 15 (2014), e371–e381.
36. [36] Hu-Lieskovan, S., Robert, L., Homet Moreno, B., Ribas, A., Combining targeted therapy with immunotherapy in BRAF-mutant melanoma: promise and challenges. J Clin Oncol 32 (2014), 2248–2254.
37. [37] Long, G.V., Menzies, A.M., Nagrial, A.M., Haydu, L.E., Hamilton, A.L., Mann, G.J., et al. Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma. J Clin Oncol 29 (2011), 1239–1246.
38. [38] Cipriani, A., Higgins, J.P., Geddes, J.R., Salanti, G., Conceptual and technical challenges in network meta-analysis. Ann Intern Med 159 (2013), 130–137.
39. [39] Salanti, G., Indirect and mixed-treatment comparison, network, or multiple-treatments meta-analysis: many names, many benefits, many concerns for the next generation evidence synthesis tool. Res Synth Methods 3 (2012), 80–97.
40. [40] Flaherty, K.T., Hennig, M., Lee, S.J., Ascierto, P.A., Dummer, R., Eggermont, A.M., et al. Surrogate endpoints for overall survival in metastatic melanoma: a meta-analysis of randomised controlled trials. Lancet Oncol 15 (2014), 297–304.
41. [41] Ribas, A., Hersey, P., Middleton, M.R., Gogas, H., Flaherty, K.T., Sondak, V.K., et al. New challenges in endpoints for drug development in advanced melanoma. Clin Cancer Res 18 (2012), 336–341.
42. [42] Hutton, B., Salanti, G., Caldwell, D.M., Chaimani, A., Schmid, C.H., Cameron, C., et al. The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations. Ann Intern Med 162 (2015), 777–784.
43. [43] Higgins, J, Green, S. Cochrane handbook for systematic reviews of interventions. Version 5.1.0 ed2011.
44. [44] Higgins, J.P., Altman, D.G., Gotzsche, P.C., Juni, P., Moher, D., Oxman, A.D., et al. The cochrane collaboration's tool for assessing risk of bias in randomised trials. BMJ, 343, 2011, d5928.
45. [45] Salanti, G., Del Giovane, C., Chaimani, A., Caldwell, D.M., Higgins, J.P., Evaluating the quality of evidence from a network meta-analysis. PLoS One, 9, 2014, e99682.
46. [46] Chaimani, A., Higgins, J.P., Mavridis, D., Spyridonos, P., Salanti, G., Graphical tools for network meta-analysis in STATA. PLoS One, 8, 2013, e76654.
47. [47] National cancer institute common terminology criteria for adverse events, Version 3.0.
48. [48] Parmar, M.K., Torri, V., Stewart, L., Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med 17 (1998), 2815–2834.
49. [49] Tierney, J.F., Stewart, L.A., Ghersi, D., Burdett, S., Sydes, M.R., Practical methods for incorporating summary time-to-event data into meta-analysis. Trials, 8, 2007, 16.
50. [50] DerSimonian, R., Laird, N., Meta-analysis in clinical trials. Control Clin Trials 7 (1986), 177–188.
51. [51] Higgins, J.P., Thompson, S.G., Deeks, J.J., Altman, D.G., Measuring inconsistency in meta-analyses. BMJ 327 (2003), 557–560.
52. [52] Borenstein, M., Hedges, L.V., Higgins, J.P.T., Rothstein, H., Multiple comparisons within a study. Introduction to meta-analysis, 2009, Wiley, Chichester.
53. [53] Hong, H., Carlin, B.P., Shamliyan, T.A., Wyman, J.F., Ramakrishnan, R., Sainfort, F., et al. Comparing Bayesian and frequentist approaches for multiple outcome mixed treatment comparisons. Med Decis Making 33 (2013), 702–714.
54. [54] White, I.R., Multivariate random-effects meta-regression: updates to mvmeta. STATA J 11 (2011), 255–270.
55. [55] Donegan, S., Williamson, P., D'Alessandro, U., Tudur, Smith C., Assessing key assumptions of network meta-analysis: a review of methods. Res Synth Meth 4 (2013), 291–323.
56. [56] Higgins, J.P., Jackson, D., Barrett, J.K., Lu, G., Ades, A.E., White, I.R., Consistency and inconsistency in network meta-analysis: concepts and models for multi-arm studies. Res Synth Meth 3 (2012), 98–110.
57. [57] White, I.R., Barrett, J.K., Jackson, D., Higgins, J.P., Consistency and inconsistency in network meta-analysis: model estimation using multivariate meta-regression. Res Synth Meth 3 (2012), 111–125.
58. [58] White, I.R., Network meta-analysis. STATA J 15 (2015), 951–985.
59. [59] Salanti, G., Ades, A.E., Ioannidis, J.P., Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial. J Clin Epidemiol 64 (2011), 163–171.
60. [60] Ribas, A., Kefford, R., Marshall, M.A., Punt, C.J., Haanen, J.B., Marmol, M., et al. Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma. J Clin Oncol 31 (2013), 616–622.
61. [61] Robert, C, Thomas, L, Bondarenko, I, O'Day, S, DJ, M, Garbe, C, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. New Engl J Med 364 (2011), 2517–2526.
62. [62] Ugurel, S., Rohmel, J., Ascierto, P.A., Flaherty, K.T., Grob, J.J., Hauschild, A., et al. Survival of patients with advanced metastatic melanoma: the impact of novel therapies. Eur J Cancer 53 (2016), 125–134.
63. [63] Edlundh-Rose, E., Egyhazi, S., Omholt, K., Mansson-Brahme, E., Platz, A., Hansson, J., et al. NRAS and BRAF mutations in melanoma tumours in relation to clinical characteristics: a study based on mutation screening by pyrosequencing. Melanoma Res 16 (2006), 471–478.
64. [64] Meckbach, D., Bauer, J., Pflugfelder, A., Meier, F., Busch, C., Eigentler, T.K., et al. Survival according to BRAF-V600 tumor mutations–an analysis of 437 patients with primary melanoma. PLoS One, 9, 2014, e86194.
65. [65] Long, G.V., Trefzer, U., Davies, M.A., Kefford, R.F., Ascierto, P.A., Chapman, P.B., et al. Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial. Lancet Oncol 13 (2012), 1087–1095.
66. [66] Di Giacomo, A.M., Ascierto, P.A., Pilla, L., Santinami, M., Ferrucci, P.F., Giannarelli, D., et al. Ipilimumab and fotemustine in patients with advanced melanoma (NIBIT-M1): an open-label, single-arm phase 2 trial. Lancet Oncol 13 (2012), 879–886.
67. [67] Margolin, K., Ernstoff, M.S., Hamid, O., Lawrence, D., McDermott, D., Puzanov, I., et al. Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial. Lancet Oncol 13 (2012), 459–465.
68. [68] Queirolo, P., Spagnolo, F., Ascierto, P.A., Simeone, E., Marchetti, P., Scoppola, A., et al. Efficacy and safety of ipilimumab in patients with advanced melanoma and brain metastases. J Neurooncol 118 (2014), 109–116.
69. [69] Weber, J.S., Gibney, G., Sullivan, R.J., Sosman, J.A., Slingluff, C.L. Jr., Lawrence, D.P., et al. Sequential administration of nivolumab and ipilimumab with a planned switch in patients with advanced melanoma (CheckMate 064): an open-label, randomised, phase 2 trial. Lancet Oncol, 2016.
70. [70] Borghaei, H., Paz-Ares, L., Horn, L., Spigel, D.R., Steins, M., Ready, N.E., et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med 373 (2015), 1627–1639.
71. [71] Ferris, R.L., Blumenschein, G. Jr., Fayette, J., Guigay, J., Colevas, A.D., Licitra, L., et al. Nivolumab for recurrent squamous-cell carcinoma of the head and neck. N Engl J Med 375 (2016), 1856–1867.
72. [72] Nghiem, P.T., Bhatia, S., Lipson, E.J., Kudchadkar, R.R., Miller, N.J., Annamalai, L., et al. PD-1 blockade with pembrolizumab in advanced merkel-cell carcinoma. N Engl J Med 374 (2016), 2542–2552.
73. [73] Nanda, R., Chow, L.Q., Dees, E.C., Berger, R., Gupta, S., Geva, R., et al. Pembrolizumab in patients with advanced triple-negative breast cancer: phase Ib KEYNOTE-012 study. J Clin Oncol 34 (2016), 2460–2467.
74. [74] Muro, K., Chung, H.C., Shankaran, V., Geva, R., Catenacci, D., Gupta, S., et al. Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial. Lancet Oncol 17 (2016), 717–726.